OTCMKTS:GMXAY

GENMAB A/S/S Competitors

$37.08

+0.38 (+1.04 %)

(As of 05/14/2021 12:00 AM ET)

Add

Compare

Today's Range

$36.90

▼

$37.55

50-Day Range

$18.35

▼

$37.40

52-Week Range

$12.10

▼

$19.00

Volume299,024 shs

Average Volume48,553 shs

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

GENMAB A/S/S (OTCMKTS:GMXAY) Vs. DDXS, TNGN, ATTBF, ADTX, AGNPF, and LBTSF

Should you be buying GMXAY stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to GENMAB A/S/S, including (DDXS) (DDXS), (TNGN) (TNGN), Abattis Bioceuticals (ATTBF), ADiTx Therapeutics (ADTX), Algernon Pharmaceuticals (AGNPF), and Almirall (LBTSF).

GENMAB A/S/S vs. (DDXS) Stock

(DDXS) (OTCMKTS:DDXS) and GENMAB A/S/S (OTCMKTS:GMXAY) are both health technology companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for (DDXS) and GENMAB A/S/S, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
(DDXS)	0	0	0	0	N/A
GENMAB A/S/S	0	0	0	0	N/A

Earnings and Valuation

This table compares (DDXS) and GENMAB A/S/S's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
(DDXS)	N/A	N/A	N/A	N/A	N/A
GENMAB A/S/S	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares (DDXS) and GENMAB A/S/S's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
(DDXS)	N/A	N/A	N/A
GENMAB A/S/S	N/A	N/A	N/A

GENMAB A/S/S vs. (TNGN) Stock

(TNGN) (OTCMKTS:TNGN) and GENMAB A/S/S (OTCMKTS:GMXAY) are both health technology companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Profitability

This table compares (TNGN) and GENMAB A/S/S's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
(TNGN)	N/A	N/A	N/A
GENMAB A/S/S	N/A	N/A	N/A

Earnings and Valuation

This table compares (TNGN) and GENMAB A/S/S's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
(TNGN)	N/A	N/A	N/A	N/A	N/A
GENMAB A/S/S	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for (TNGN) and GENMAB A/S/S, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
(TNGN)	0	0	0	0	N/A
GENMAB A/S/S	0	0	0	0	N/A

GENMAB A/S/S vs. Abattis Bioceuticals Stock

Abattis Bioceuticals (OTCMKTS:ATTBF) and GENMAB A/S/S (OTCMKTS:GMXAY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.

Profitability

This table compares Abattis Bioceuticals and GENMAB A/S/S's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Abattis Bioceuticals	N/A	N/A	N/A
GENMAB A/S/S	N/A	N/A	N/A

Valuation and Earnings

This table compares Abattis Bioceuticals and GENMAB A/S/S's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abattis Bioceuticals	N/A	N/A	N/A	N/A	N/A
GENMAB A/S/S	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Abattis Bioceuticals and GENMAB A/S/S, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abattis Bioceuticals	0	0	0	0	N/A
GENMAB A/S/S	0	0	0	0	N/A

GENMAB A/S/S vs. ADiTx Therapeutics Stock

ADiTx Therapeutics (NASDAQ:ADTX) and GENMAB A/S/S (OTCMKTS:GMXAY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.

Profitability

This table compares ADiTx Therapeutics and GENMAB A/S/S's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ADiTx Therapeutics	N/A	N/A	N/A
GENMAB A/S/S	N/A	N/A	N/A

Valuation and Earnings

This table compares ADiTx Therapeutics and GENMAB A/S/S's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADiTx Therapeutics	N/A	N/A	N/A	N/A	N/A
GENMAB A/S/S	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for ADiTx Therapeutics and GENMAB A/S/S, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADiTx Therapeutics	0	0	1	0	3.00
GENMAB A/S/S	0	0	0	0	N/A

Summary

ADiTx Therapeutics beats GENMAB A/S/S on 1 of the 1 factors compared between the two stocks.

GENMAB A/S/S vs. Algernon Pharmaceuticals Stock

Algernon Pharmaceuticals (OTCMKTS:AGNPF) and GENMAB A/S/S (OTCMKTS:GMXAY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.

Profitability

This table compares Algernon Pharmaceuticals and GENMAB A/S/S's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Algernon Pharmaceuticals	N/A	N/A	N/A
GENMAB A/S/S	N/A	N/A	N/A

Valuation and Earnings

This table compares Algernon Pharmaceuticals and GENMAB A/S/S's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Algernon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GENMAB A/S/S	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Algernon Pharmaceuticals and GENMAB A/S/S, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Algernon Pharmaceuticals	0	0	0	0	N/A
GENMAB A/S/S	0	0	0	0	N/A

GENMAB A/S/S vs. Almirall Stock

Almirall (OTCMKTS:LBTSF) and GENMAB A/S/S (OTCMKTS:GMXAY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.

Profitability

This table compares Almirall and GENMAB A/S/S's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Almirall	N/A	N/A	N/A
GENMAB A/S/S	N/A	N/A	N/A

Valuation and Earnings

This table compares Almirall and GENMAB A/S/S's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Almirall	N/A	N/A	N/A	N/A	N/A
GENMAB A/S/S	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Almirall and GENMAB A/S/S, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Almirall	0	1	1	0	2.50
GENMAB A/S/S	0	0	0	0	N/A

Summary

Almirall beats GENMAB A/S/S on 1 of the 1 factors compared between the two stocks.